THIS IS HUGE! A new nasal COVID-19 vaccine BLOCKS transmission of the virus, according to a recent study out of Washington University. This suggests vaccines delivered directly to the nose or mouth could play a critical role in containing the spread of respiratory infections.🧵⬇️
A new study by researchers at Washington University School of Medicine in St. Louis indicates that next-generation vaccines that target the virus’s points of entry- the nose and mouth- may be able to do what traditional shots cannot: contain the spread of respiratory infections
AND prevent transmission.
Using a nasal COVID-19 vaccine based on Washington University technology, approved for use in India and licensed to Ocugen for further development in the U.S., the researchers showed that vaccinated hamsters that developed infections did not pass the
virus on to others, BREAKING the cycle of transmission. In contrast, an approved COVID-19 vaccine that is injected failed to prevent the spread of the virus.
The findings, published July 31st in Science Advances, provide further evidence that so-called mucosal vaccines sprayed
into the nose or dropped into the mouth may be the key to controlling respiratory infections such as influenza and COVID-19 that continue to circulate and cause significant illness and death.
For this study, researchers developed and validated a model for community transmission using hamsters and then used it to assess the effect of mucosal vaccination on the spread of SARS-CoV-2. (Unlike mice, hamsters are naturally susceptible to infection with SARS-CoV-2,
making them the ideal laboratory animals for a transmission study.)
The researchers immunized groups of hamsters with laboratory versions of approved COVID-19 vaccines: the nasal iNCOVACC used in India or the injected Pfizer vaccine. For comparison, some hamsters were not
immunized. After giving the vaccinated hamsters a few weeks for their immune responses to fully mature, the researchers infected other hamsters with SARS-CoV-2 and then placed the immunized hamsters with the infected hamsters for eight hours. This first step of the experiment
mimics the experience of vaccinated people who are exposed to a person with COVID-19.
After spending eight hours rubbing shoulders with infected hamsters, most of the vaccinated animals became infected. Virus was found in the noses and lungs of 12 of 14 (86%) hamsters that had
received the nasal vaccine, and 15 of 16 (94%) hamsters that had received the injected vaccine. Importantly, while most animals in both groups were infected, they weren’t infected to the same degree. Hamsters that had been nasally immunized had virus levels in the airways
100 to 100,000 times lower than those that had received the shot or had not been vaccinated. The study did not assess the animals’ health, but previous studies have shown that both vaccines reduce the likelihood of severe illness and death from COVID-19.
The second step of the experiment yielded even more striking results. The researchers took vaccinated hamsters that subsequently developed infections and placed them with healthy vaccinated and unvaccinated hamsters for eight hours to model transmission of virus from a vaccinated
person to others.
None of the hamsters that were exposed to nasally vaccinated hamsters became infected, regardless of whether the recipient hamster had been vaccinated or not. In contrast, roughly half of the hamsters that were exposed to hamsters vaccinated by injection
became infected- again, regardless of the recipient’s immunization status. In other words, vaccination through the nose BROKE the cycle of transmission. You can read all this and more here:
•
•science.org/doi/10.1126/sc… medicine.wustl.edu/news/nasal-cov…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
HOW COOL IS THIS? Researchers at the University of Illinois have developed a new dual-action antibiotic that could make bacterial resistance nearly impossible. Macrolones can work two different ways- either by interfering with protein production or corrupting DNA structure!🧵⬇️
Researchers have combined the bacteria-killing actions of two classes of antibiotics into one, demonstrating that their new antibiotic could make bacterial resistance (almost) an impossibility. The study has been published in Nature Chemical Biology.
•nature.com/articles/s4158…
Pathogens such as bacteria threaten human health, so we dole out antibiotics. The bacteria then develop resistance to the antibiotics. While bacterial threat remains the same, our treatment arsenal is less effective, if it’s effective at all. In essence, that’s the problem caused
THIS IS HUGE! Researchers at Northwestern Medicine and Brigham and Women’s Hospital have discovered a molecular defect that promotes the pathologic immune response in Lupus and show that reversing this defect may potentially reverse the disease!
Let’s talk about that! 🧵⬇️
The study has been published in Nature.
•
Lupus- officially known as systemic lupus erythematosus (SLE)- is an autoimmune disease that affects more than 1.5 million people in the U.S. Until this new study, the causes of this disease were unclear.nature.com/articles/s4158…
Lupus can result in life-threatening damage to multiple organs including the kidneys, brain and heart. Existing treatments often fail to control the disease and have unintended side effects of reducing the immune system’s ability to fight infections.
Here Is All You NEED TO KNOW About The Updated COVID-19 Shots Planned For This Fall.
Thank You For Reading! 🧵⬇️
🎨: @sherwiind
IT IS TIME FOR AN UPDATE THREAD. Many of you have had questions in regard to schedules and updated COVID-19 vaccines. I have some news for you!
Here is all you NEED TO KNOW About the New COVID-19 Vaccines Available THIS FALL.
The FDA and CDC have greenlighted updated COVID vaccines from Pfizer, Moderna AND Novavax. The shots are formulated to target the "FLiRT" variants. KP.3 was identified this spring and has become the top variant since. This variant is part of the “FLiRT” family of variants.
THIS IS HUGE! Researchers at JHU have identified the Aplp1 protein, which facilitates the spread of harmful alpha-synuclein proteins in the brain as a novel therapeutic target for Parkinson’s disease AND a potential therapy using an EXISTING FDA-approved cancer drug.🧵⬇️
In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson’s disease-causing alpha-synuclein.
THIS IS HUGE! For the FIRST time, an HIV PrEP drug candidate in the form of a twice-yearly subcutaneous shot has shown ZERO infections in a late-stage Phase III trial. Lenacapavir was 100% effective at preventing HIV in MORE THAN 2,000 participants.
These results come from the PURPOSE 1 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in women and adolescent girls ages 16 to 25 in South Africa and Uganda. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the
THIS IS HUGE! Researchers at the University of Illinois have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections (MORE THAN 130 multidrug-resistant bacterial strains, in fact) while sparing the gut microbiome!
Let’s talk about that!🧵⬇️
The findings were recently published in Nature.
•
The study looked at the development of an antibiotic that targets gram-negative bacteria without disturbing the gut microbiome.nature.com/articles/s4158…
Researchers identified the antibiotic lolamicin, which disrupts a particular system called the Lol lipoprotein transport system.
•ncbi.nlm.nih.gov/pmc/articles/P…